Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Olga Radkevich-Brown"'
Supplementary Figure 1 from Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic Mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82c9c1ff5560d91dee2499879381b390
https://doi.org/10.1158/0008-5472.22376465
https://doi.org/10.1158/0008-5472.22376465
Autor:
Wei-Zen Wei, Augusto Amici, Amy Weise, Joyce D. Reyes, Marie P. Piechocki, Richard F. Jones, Olga Radkevich-Brown, Elena Quaglino, Jennifer B. Jacob
Supplementary Figures 1-2 from Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0143178b025588468d0f870cddf7a54c
https://doi.org/10.1158/0008-5472.22383269.v1
https://doi.org/10.1158/0008-5472.22383269.v1
Autor:
Wei-Zen Wei, Augusto Amici, Amy Weise, Joyce D. Reyes, Marie P. Piechocki, Richard F. Jones, Olga Radkevich-Brown, Elena Quaglino, Jennifer B. Jacob
Immune tolerance to tumor-associated self-antigens poses a major challenge in the ability to mount an effective cancer vaccine response. To overcome immune tolerance to HER-2, we formulated DNA vaccines that express both human HER-2 and heterologous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1b868fdfd6a261068c380de529152dd
https://doi.org/10.1158/0008-5472.c.6500483
https://doi.org/10.1158/0008-5472.c.6500483
Supplementary Figure 1 Legend from Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic Mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cb65fb4886078967666f9f8c7c06b48
https://doi.org/10.1158/0008-5472.22376468
https://doi.org/10.1158/0008-5472.22376468
Publikováno v:
Journal of Wound, Ostomy & Continence Nursing. 46:256-262
Background Recent revisions to the pressure injury staging system include guidance on differential diagnoses for deep tissue pressure injury (DTPI). Accurately identifying DTPI is critical; however, purpura in the setting of vascular disorders and sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b62e9356d1eb8744202298f43021c3
https://doi.org/10.1097/won.0000000000000525
https://doi.org/10.1097/won.0000000000000525
Publikováno v:
Pediatric Dermatology. 30:736-740
Bullous dermolysis of the newborn (BDN) is a subtype of dystrophic epidermolysis bullosa caused by mutations in type VII collagen resulting in disorganized anchoring fibrils and sublamina densa blister formation. Disease activity is usually confined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b0fac0302fce8643d44d450fe5e277f
https://doi.org/10.1111/pde.12230
https://doi.org/10.1111/pde.12230
Publikováno v:
Molecular Therapy. 21:91-100
Epidermal growth factor receptor (EGFR) over-signaling leads to more aggressive tumor growth. The antitumor effect of Cetuximab, an anti-EGFR antibody, depends on oncogenic-signal blockade leading to tumor cell apoptosis and antibody dependent cell-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93f79672e7b53beba50961bf911f8b61
https://doi.org/10.1038/mt.2012.184
https://doi.org/10.1038/mt.2012.184
Autor:
Joyce D. Reyes, Amy Weise, Elena Quaglino, Olga Radkevich-Brown, Marie P. Piechocki, Richard F. Jones, Wei Zen Wei, Augusto Amici, Jennifer B. Jacob
Publikováno v:
Cancer Research. 70:119-128
Immune tolerance to tumor-associated self-antigens poses a major challenge in the ability to mount an effective cancer vaccine response. To overcome immune tolerance to HER-2, we formulated DNA vaccines that express both human HER-2 and heterologous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9686bc7b0589f319fa5ce65363a829b2
https://doi.org/10.1158/0008-5472.can-09-2554
https://doi.org/10.1158/0008-5472.can-09-2554
Publikováno v:
Cancer Research. 69:212-218
Genetic regulation of immune reactivity to Her-2 vaccination and the consequent antitumor effect was tested in human Her-2 transgenic (Tg) mice of C57BL/6 (B6), BALB/c (BALB), and (B6x BALB) F1 (F1) background. Mice were electrovaccinated with Her-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::343673bef6320fa0693fd016c6ef4bef
https://doi.org/10.1158/0008-5472.can-08-3092
https://doi.org/10.1158/0008-5472.can-08-3092
Autor:
Zhujun Jiang, Jie Tang, Shengdian Wang, Yang Wang, Liufu Deng, Yang Xin Fu, Husain Sattar, Eric D. Mortenson, Sae Gwang Park, Nicholas K. Brown, Yang Liu, Mark I. Greene, Olga Radkevich-Brown, Xuanming Yang
Publikováno v:
Cancer cell. 18(2)
SummaryAnti-HER2/neu antibody therapy is reported to mediate tumor regression by interrupting oncogenic signals and/or inducing FcR-mediated cytotoxicity. Here, we demonstrate that the mechanisms of tumor regression by this therapy also require the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dc29beb1494da19e595523fbadc87de
https://pubmed.ncbi.nlm.nih.gov/20708150
https://pubmed.ncbi.nlm.nih.gov/20708150